API companies are accelerating the expansion of production capacity, which is having a positive impact on the pharmaceutical machine industry

[Pharmaceutical Network Market Analysis] With the accelerating development of the pharmaceutical industry, the scale of China's API market has been growing in recent years
.

It has risen from US$130.
8 billion in 2015 to US$175 billion in 2019, with a compound annual growth rate of 7.
5%
.

According to this development trend, the industry predicts that the scale of China's API industry may exceed 250 billion yuan in 2022
.

It is worth noting that due to the continuous expansion of the market demand for APIs, many domestic API companies have begun to expand production, and are trying to seize the market high ground in this field through new production projects
.

 API companies are accelerating the expansion of production capacity (Source: Pharmaceutical Network) In order to expand the production capacity of APIs, a group of companies are vigorously building new production projects.
On March 16, Orient announced that the company plans to invest a total of 637,875,100 yuan.
It is planned to build a new production line project with an annual output of 308 tons of characteristic raw materials and 200 million tablets of anti-tumor preparations in the Cangshan industrial agglomeration area in Tiantai
.

The announcement shows that in order to realize the long-term development of the company, give full play to its own technological and market advantages, expand the export of advantageous raw materials, meet the customer's CDMO business needs, expand the preparation market, and ensure sufficient production capacity, Orient plans to develop in Tiantai Cangshan Industrial Cluster Area.
A new production line project with an annual output of 308 tons of characteristic raw materials and 200 million antitumor preparations
.

It is reported that the project includes a total of 7 APIs and 4 preparation products
.

The total planned investment of the project is 637.
8751 million yuan, and the planned construction period is two years
.

According to preliminary estimates, after the project is put into production, the average annual output value is 1 billion yuan, and the average annual total profit and tax is 350 million yuan
.

 　　On March 9, Beilu Pharmaceutical also announced again that it expected to invest 192 million yuan to start the construction of the "Cangzhou Phase III Raw Material Production Project"
.

The integration of "APIs + preparations" is the key layout of Beilu Pharmaceutical's strategic development in recent years, and the construction of contrast agent APIs is one of the company's key tasks
.

It is reported that Beilu Pharmaceutical's "Cangzhou Phase III Raw Material Production Project" will build a new API production workshop within the reserved land of the Cangzhou plant.
The construction period is 2 years and the planned total investment is 192.
4414 million yuan
.

 　　According to the plan, the project covers the production of gadolinium series contrast agent raw materials and pharmaceutical excipients such as gadobutrol and gadoteric acid meglumine, as well as the expansion of the intermediate products of Jiuwei Zhenxin Granules
.

 　　In addition to the above companies, in recent years, including Hendi Pharmaceutical, Aoxiang Pharmaceutical, Fuxiang Co.
, Ltd.
, Tianyu Co.
, Ltd.
, Anglikang, Xianju Pharmaceutical, etc.
, have also announced fixed increase plans.
The funds raised are all used to expand production and raise funds.
Most of the products put into the market are in the introduction period or the rapid volume period
.

The industry believes that from the above point of view, it can fully reflect the high prosperity of China's API industry.
In the future, a large number of enterprises will achieve economies of scale by further expanding the layout and production capacity of APIs and pharmaceutical excipients.
Advantages and competitive advantages, thereby enhancing the company's profitability and core competitiveness
.

 　　The transformation and upgrading of the API industry has become the general trend.
Although the API market is developing continuously, the industry also pointed out that the entire industry is currently facing many challenges; for example, under the pressure of a series of energy-saving and emission reduction policies, API companies are facing More and more strict environmental supervision, quality improvement and other issues
.

Industry analysts believe that these factors may further force raw material companies to upgrade related pharmaceutical equipment and generate more demand
.

 　　In fact, in different production links of APIs, a large number of production equipments with different missions are required
.

Such as equipment used for synthesis reaction, fermentation, extraction, crystallization, metering and material storage, such as reaction tanks, fermentation tanks, extraction equipment, etc.
; equipment used for solid-liquid separation, such as sterilization filters, filter presses and other filtration equipment, etc.

.

Therefore, under the background of upgrading and expanding production of API companies, pharmaceutical equipment companies will also play an increasingly important role and face more new demands
.

 　　It is understood that many domestic pharmaceutical equipment companies have taken action in order to meet the needs of related companies to upgrade and expand production, and many companies are already building safer, greener, energy-saving, and efficient equipment and solutions
.

It is worth mentioning that among the two innovative overall solutions for sterile products released by Chutian Technology in November last year, there is an overall solution for aseptic freeze-dried API isolators
.

According to reports, the overall solution is developed for the sterile freeze-dried API market, which can realize the continuity of freeze-drying, discharging, pulverizing, mixing and sub-packaging processes.
low-carbon requirements
.

At the same time, it can also help users reduce operation and maintenance costs, and reduce the impact of dust diffusion on the environment and personnel
.

 　　Conclusion In general, while China's API companies continue to expand production, they will continue to develop towards a high-quality global standardization and standardization
.

In order to meet the increasing demand of domestic enterprises in API pharmaceuticals, domestic API production equipment manufacturing enterprises are expected to be continuously forced to increase investment in R&D and achieve more new breakthroughs in high-end fields
.